食管切除术后寡转移灶治疗后的生存预测因素
该回顾性研究纳入1988至2015年间640例治愈性食管切除术患者,其中241例(37.7%)复发,56例(9%)接受孤立性复发的根治性治疗。多变量分析显示,复发时间(TTR)是复发后生存的唯一显著独立预测因素(HR 0.98,95%CI 0.96-0.99,P=0.034),手术联合或不联合放化疗与单纯根治性放化疗在无病生存或复发后生存方面无显著差异。
要点
- 根治性食管切除术后241例(37.7%)复发,56例(9%)接受孤立性复发的根治性治疗。
- 复发时间(TTR)是复发后生存的唯一显著独立预测因素(HR 0.98,95%CI 0.96-0.99,P=0.034)。
- 手术联合或不联合放化疗与单纯根治性放化疗在无病生存或复发后生存方面无显著差异。
核心结论
- 经过选择的孤立性食管癌复发患者可接受根治性治疗,复发时间(TTR)是复发后生存的最佳预测因素。
研究设计与样本
- 回顾性分析前瞻性数据库(1988至2015年),纳入640例治愈性食管切除术后复发患者,其中56例接受孤立性复发的根治性治疗。
主要发现
- 640例治愈性食管切除术中241例(37.7%)复发,中位随访50个月。
- 56例(9%)接受孤立性复发的根治性治疗,其中31例手术联合或不联合放化疗,25例单纯根治性放化疗。
- 中位复发时间(TTR)为19个月;1年和3年复发后生存率分别为78%和38%,中位生存26个月。
- 多变量分析显示,TTR是复发后生存的唯一显著独立预测因素(HR 0.98,95%CI 0.96-0.99,P=0.034)。
- 手术联合或不联合放化疗组与单纯根治性放化疗组在无病生存或复发后生存方面无显著差异。
关键数值与推荐
- 复发后生存的独立预测因素:TTR(HR 0.98,95%CI 0.96-0.99,P=0.034)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent esophageal carcinoma (EC) has a dismal prognosis. However, prior studies showed that selected patients with isolated recurrence may benefit from definitive therapy. The aim of this study was to identify the predictors of postrecurrence survival (PRS) in patients with isolated EC recurrence who were treated with curative intent. METHODS: A retrospective review of a prospective database (1988 to 2015) was performed to identify all recurrent EC patients after curative esophagectomy. Demographic and clinicopathologic data were reviewed. The probability of PRS was estimated with the Kaplan-Meier method. Predictors of PRS after definitive therapy for isolated EC recurrence were determined by the multivariable Cox proportional hazards model. RESULTS: Of the 640 curative esophagectomies, 241 patients (37.7%) experienced recurrences (median follow-up 50 months). Fifty-six patients (9%) received definitive treatment of isolated EC recurrence (31 were treated surgically with or without chemotherapy-radiotherapy [CTRT] and 25 received definitive CTRT alone). Median time to recurrence (TTR) was 19 months. The 1- and 3-year PRSs were 78% and 38% (median survival 26 months). On multivariable analysis; TTR was the only significant independent predictor for survival after recurrence (hazards ratio 0.98, 95% confidence interval: 0.96 to 0.99, p = 0.034). No pronounced difference was found in disease-free survival or in PRS between recurrent patients treated with operation with or without CTRT and patients who received definitive CTRT. CONCLUSIONS: A select subgroup of patients with isolated EC recurrence can be treated with curative intent. TTR was the best predictor for PRS.
引用
- Ghaly G, Harrison S, Kamel MK, et al. Predictors of Survival After Treatment of Oligometastases After Esophagectomy. Ann Thorac Surg. 2017. PMID: 29275824. doi:10.1016/j.athoracsur.2017.10.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。